A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy

Further Publications Immunology

Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial

N Engl J Med

Perkovic V, Trimarchi H, Tesar V, Lafayette R, Wong MG, Barratt J, Suzuki Y, Liew A, Zhang H, Carroll K, Jha V, Quevedo A, Han SH, Praga M, Chacko B, Sahay M, Cheung CK, Kooienga L, Walsh M, Xia J, Fajardo C, Shah L, Hafkin J, Rizk DV, VISIONARY Trial Investigators Group

doi: 10.1056/NEJMoa2512133

Autoimmune Disease

Dupilumab in Patients With Chronic Spontaneous Urticaria: Phase 3 LIBERTY-CSU CUPID Randomized Clinical Trials

JAMA Dermatol

Casale TB, Saini SS, Ben-Shoshan M, Giménez-Arnau AM, Bernstein JA, Hayama K, Amin N, Robinson LB, Bauer D, Dakin P, Laws E, Radin A, Makhija M

doi: 10.1001/jamadermatol.2025.6023

Allergic Diseases

Epinephrine Nasal Spray Improves Allergic Symptoms in Patients Undergoing Oral Food Challenge, Phase 3 Trial

J Allergy Clin Immunol Pract

Ebisawa M, Takahashi K, Takahashi K, Yanagida N, Sato S, Lieberman J, Pistiner M, Spergel JM, Lowenthal R, Tanimoto S

doi: 10.1016/j.jaip.2025.06.038

Further Publications Dermatology

Post-exposure prophylaxis regimen of rabies monoclonal antibody and vaccine in category 3 potential exposure patients: a phase 4, open-label, randomised, active-controlled trial

Lancet

Kulkarni PS, Potey AV, Kapse D, Bhamare C, Gawande A, Munshi R, Pawar S, Gogtay NJ, Agarwal A, Tambe M, Thakre S, Samuel CJ, Khan SMS, S RH, Rana D, Singh N, Kamath V, Bhalla HL, Poonawalla CS, Mani RS, Gunale B, RAB-04 study group

doi: 10.1016/S0140-6736(25)00735-4

Acne

Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension

J Am Acad Dermatol

Sayed CJ, Kirby B, Garg A, Naik HB, Kimball AB, Zouboulis CC, Jemec GBE, Kokolakis G, Ingram JR, Morita A, Deherder D, Crater C, Rolleri RL, Vaux T, Lambert J, Lukowski B, Bechara FG

doi: 10.1016/j.jaad.2025.11.031

Psoriasis

Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial

JAMA Dermatol

Gooderham MJ, Alonso-Llamazares J, Bagel J, Bhatia N, Bukhalo M, DuBois J, Ferris LK, Green L, Kircik LH, Lockshin B, Loo WJ, Papp KA, Soung J, Seal MS, Snyder S, Kato S, Krupa D, Burnett P, Berk DR, Chu DH

doi: 10.1001/jamadermatol.2025.1136

Atopic Dermatitis

Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

J Am Acad Dermatol

Bissonnette R, Gold LS, Kircik L, Simpson EL, Eichenfield LF, Browning J, Hebert AA, Alexis AF, Soong W, Piscitelli SC, Tallman AM, Rubenstein DS, Brown PM, Silverberg JI

doi: 10.1016/j.jaad.2025.05.1391

Further Publications Dermatology

Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial

Lancet

Luckey A, Balasegaram M, Barbee LA, Batteiger TA, Broadhurst H, Cohen SE, Delany-Moretlwe S, de Vries HJC, Dionne JA, Gill K, Kenyon C, Kittiyaowamarn R, Lewis D, Mueller JP, Naicker V, O'Brien S, O'Donnell JP, Phanuphak N, Spooner E, Srinivasan S, Taylor SN, Unemo M, Zwane Z, Hook EW 3rd, Zoliflodacin Phase 3 Study Group

doi: 10.1016/S0140-6736(25)01953-1

Systemic Lupus Erythematosus

A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus